Abeona Therapeutics Inc.
ABEO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | – | 75% | – | – |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | – | 31,517.5% | – | – |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | – | 27,208.3% | – | – |
| EPS Diluted | -0.1 | 1.71 | -0.24 | -0.23 |
| % Growth | -105.8% | 812.5% | -4.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |